Journal
ONCOTARGET
Volume 7, Issue 35, Pages 56471-56479Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.10602
Keywords
carbonic anhydrase IX; positron emission tomography; molecular imaging; renal cell carcinoma; copper-64
Categories
Funding
- [CA134675]
- [CA184228]
- [CA183031]
- [CA197470]
Ask authors/readers for more resources
Carbonic anhydrase IX (CAIX) is a cell surface enzyme that is over-expressed in approximately 95% of cases of clear cell renal cell carcinoma (ccRCC), the most common renal cancer. We synthesized and performed in vitro and in vivo evaluation of a dual-motif ligand, [Cu-64]XYIMSR-06, for imaging CAIX expression on ccRCC tumors using positron emission tomography (PET). [Cu-64] XYIMSR-06 was generated in yields of 51.0 +/- 4.5% (n=5) and specific activities of 4.1 - 8.9 GBq/mu mol (110-240 Ci/mmol). Tumor was visualized on PET images by 1 h post-injection with high tumor-to-background levels (>100 tumor-to-blood and - muscle) achieved within 24 h. Biodistribution studies demonstrated a maximum tumor uptake of 19.3% injected dose per gram of radioactivity at 4 h. Tumor-to-blood, - muscle and - kidney ratios were 129.6 +/- 18.8, 84.3 +/- 21.0 and 2.1 +/- 0.3, respectively, at 8 h post-injection. At 24 h a tumor-to-kidney ratio of 7.1 +/- 2.5 was achieved. These results indicate pharmacokinetics superior to those of previously reported imaging agents binding to CAIX. [Cu-64] XYIMSR-06 is a new low-molecular-weight PET ligand targeting CAIX, which can image localized and metastatic ccRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available